Overview
Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures. In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status. Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.
Indication
Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Associated Conditions
- Edematous Fibrosclerotic Panniculopathy (Cellulite)
- Hypothyroidism
- Localized Adiposity
- Myxedema coma
- Euthyroid Goitre
- Thyrotropin dependent Well-Differentiated Thyroid Cancer
Research Report
Levothyroxine (DB00451): A Comprehensive Monograph on its Pharmacology, Clinical Use, and Evolving Therapeutic Landscape
Section 1: Foundational Characteristics of Levothyroxine
This section establishes the fundamental identity of Levothyroxine, providing the chemical and physical context necessary for understanding its pharmacological behavior.
1.1. Chemical Identity and Physicochemical Properties
Levothyroxine is a synthetically manufactured small molecule drug, identified unequivocally by its Chemical Abstracts Service (CAS) Number 51-48-9 and its DrugBank accession number DB00451.[1] It is the levorotatory (L) stereoisomer of thyroxine (T4), the primary hormone synthesized and secreted by the thyroid gland.[1] This specific stereochemistry is paramount for its biological activity and receptor binding affinity.
The molecular structure of Levothyroxine is defined by the chemical formula C15H11I4NO4, corresponding to a molecular weight of approximately 776.87 g/mol.[1] Structurally, it is a tetraiodinated derivative of the amino acid tyrosine, featuring two phenyl rings linked by an ether oxygen. Each phenyl ring is substituted with two iodine atoms, which are critical for its hormonal function.[1] The precise chemical name, reflecting its structure and stereochemistry, is (2S)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoic acid.[5] Reflecting its long history and widespread use in clinical and research settings, Levothyroxine is known by an extensive list of synonyms, including L-T4, 3,3',5,5'-Tetraiodo-L-thyronine, and O-(4-Hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine.[1]
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/09/14 | Phase 3 | Completed | |||
2023/04/21 | Phase 2 | Completed | |||
2023/04/07 | Phase 2 | Completed | |||
2023/02/03 | Phase 2 | Active, not recruiting | |||
2022/09/02 | Phase 2 | Recruiting | |||
2022/06/09 | Phase 2 | Completed | |||
2022/05/23 | N/A | Completed | OMER B ABDELBASIT | ||
2022/05/12 | Phase 4 | Completed | Federico II University | ||
2022/04/07 | Phase 3 | Recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
2022/03/11 | N/A | Recruiting |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
A-S Medication Solutions | 50090-6880 | ORAL | 0.112 mg in 1 1 | 11/8/2023 | |
Mylan Pharmaceuticals Inc. | 0378-1811 | ORAL | 112 ug in 1 1 | 8/31/2020 | |
Mylan Pharmaceuticals Inc. | 0378-1800 | ORAL | 25 ug in 1 1 | 8/31/2020 | |
NorthStar RxLLC | 72603-664 | ORAL | 100 ug in 1 1 | 4/15/2025 | |
REMEDYREPACK INC. | 70518-3208 | ORAL | 50 ug in 1 1 | 6/2/2025 | |
Major Pharmaceuticals | 0904-6956 | ORAL | 0.15 mg in 1 1 | 2/4/2020 | |
IBSA Pharma Inc. | 71858-0105 | ORAL | 13 ug in 1 mL | 11/30/2023 | |
Bryant Ranch Prepack | 63629-2094 | ORAL | 300 ug in 1 1 | 7/23/2020 | |
A-S Medication Solutions | 50090-5661 | ORAL | 50 ug in 1 1 | 7/23/2020 | |
NuCare Pharmaceuticals,Inc. | 68071-4866 | ORAL | 100 ug in 1 1 | 2/17/2021 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
LEVOTHYROXINE SCP levothyroxine sodium 50 microgram un-coated tablet blister pack | 374936 | Medicine | A | 12/23/2022 | |
OROXINE levothyroxine sodium 100 microgram tablet blister pack | 125499 | Medicine | A | 5/17/2006 | |
LEVOTHOX levothyroxine sodium 88 microgram tablet bottle | 363989 | Medicine | A | 7/25/2022 | |
ELTROXIN levothyroxine sodium 25 microgram tablet bottle | 206944 | Medicine | A | 5/19/2014 | |
ELTROXIN levothyroxine sodium 112 microgram tablet bottle | 206967 | Medicine | A | 5/19/2014 | |
LEVOTHYROXINE GH levothyroxine sodium 75 microgram tablet bottle pack | 365690 | Medicine | A | 3/31/2023 | |
LEVOTHYROXINE LUP levothyroxine sodium 25 microgram un-coated tablet blister pack | 374926 | Medicine | A | 12/23/2022 | |
ELTROXIN levothyroxine sodium 150 microgram tablet bottle | 206946 | Medicine | A | 5/19/2014 | |
LEVOTHYROXINE LUP levothyroxine sodium 100 microgram un-coated tablet blister pack | 374929 | Medicine | A | 12/23/2022 | |
APO-LEVOTHYROXINE levothyroxine sodium 150 microgram un-coated tablet blister pack | 374924 | Medicine | A | 12/23/2022 |
Health Canada Drug Approvals
View More Health Canada Approvals
Sign in to access additional Health Canada approved drug information with detailed regulatory data.
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
APO-LEVOTHYROXINE | 02550741 | Tablet - Oral | 112 MCG | 3/17/2025 | |
TIROCAP | 02508516 | Capsule - Oral | 75 MCG | N/A | |
APO-LEVOTHYROXINE | 02550733 | Tablet - Oral | 88 MCG | 3/17/2025 | |
TIROCAP | 02508583 | Capsule - Oral | 175 MCG | N/A | |
TIROCAP | 02508567 | Capsule - Oral | 137 MCG | N/A | |
SYNTHROID | BGP Pharma ULC | 02172119 | Tablet - Oral | 125 MCG | 12/31/1996 |
LEVOTHYROXINE SODIUM FOR INJECTION | avir pharma inc. | 02461714 | Powder For Solution - Intramuscular
,
Intravenous | 200 MCG / VIAL | 11/15/2019 |
LEVOTEC 175MCG TABLETS USP | technilab pharma inc. | 02237220 | Tablet - Oral | 175 MCG / TAB | 9/8/1998 |
SYNTHROID TAB 88MCG USP | boots pharmaceuticals ltd. | 01980963 | Tablet - Oral | 88 MCG | 12/31/1993 |
SYNTHROID TAB 112MCG USP | boots pharmaceuticals ltd. | 01980947 | Tablet - Oral | 112 MCG | 12/31/1993 |
CIMA AEMPS Drug Approvals
View More CIMA AEMPS Approvals
Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
View More Philippines FDA Approvals
Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
View More Saudi SFDA Approvals
Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
View More Malaysia NPRA Approvals
Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
View More UK EMC Drug Information
Sign in to access additional UK EMC drug information with detailed pharmaceutical data.
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.